Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Outlook Therapeutics (NASDAQ: OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, announced its participation in the 8th Annual OIS Retina Innovation Summit. The company's CEO, Bob Jahr, will present during the Innovation Showcase session on July 29, 2025, from 8:35 鈥� 9:35 AM PT in Long Beach, California.
Outlook Therapeutics (NASDAQ: OTLK), un'azienda biofarmaceutica specializzata in trattamenti a base di bevacizumab per le malattie retiniche, ha annunciato la sua partecipazione all'8掳 Summit Annuale di Innovazione OIS Retina. Il CEO dell'azienda, Bob Jahr, presenter脿 durante la sessione Innovation Showcase il 29 luglio 2025, dalle 8:35 alle 9:35 AM PT a Long Beach, California.
Outlook Therapeutics (NASDAQ: OTLK), una empresa biofarmac茅utica especializada en tratamientos con bevacizumab para enfermedades de la retina, anunci贸 su participaci贸n en la 8陋 Cumbre Anual de Innovaci贸n OIS Retina. El CEO de la compa帽铆a, Bob Jahr, presentar谩 durante la sesi贸n Innovation Showcase el 29 de julio de 2025, de 8:35 a 9:35 AM PT en Long Beach, California.
Outlook Therapeutics (NASDAQ: OTLK)電� 毵濍 歆堩櫂鞚� 鞙勴暅 氩犽皵鞁滌＜毵� 旃橂鞐� 韸鬼檾霅� 靸濍獏瓿淀暀 須岇偓搿�, 鞝�8須� 鞐半 OIS 毵濍 順侅嫚 靹滊皨鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� CEO鞚� Bob Jahr臧� 2025雲� 7鞗� 29鞚� 鞓れ爠 8鞁� 35攵勲秬韯� 9鞁� 35攵勱箤歆�(韮滍弶鞏� 鞁滉皠) 旌橂Μ韽媹鞎� 搿彪箘旃橃棎靹� 鞐措Μ電� Innovation Showcase 靹胳厴鞐愳劀 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
Outlook Therapeutics (NASDAQ : OTLK), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les traitements au bevacizumab pour les maladies de la r茅tine, a annonc茅 sa participation au 8e Sommet annuel d'innovation OIS Retina. Le PDG de l'entreprise, Bob Jahr, pr茅sentera lors de la session Innovation Showcase le 29 juillet 2025, de 8h35 脿 9h35 PT 脿 Long Beach, Californie.
Outlook Therapeutics (NASDAQ: OTLK), ein biopharmazeutisches Unternehmen, das sich auf Bevacizumab-Behandlungen f眉r Netzhauterkrankungen spezialisiert hat, gab seine Teilnahme am 8. j盲hrlichen OIS Retina Innovation Summit bekannt. Der CEO des Unternehmens, Bob Jahr, wird w盲hrend der Innovation Showcase-Sitzung am 29. Juli 2025 von 8:35 bis 9:35 Uhr PT in Long Beach, Kalifornien, pr盲sentieren.
- None.
- None.
ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the being held on July 29, 2025 in Long Beach CA.
Details for the presentations are as follows:
Session: Innovation Showcase
Presenter: of Outlook Therapeutics
Date and Time: Tuesday, July 29, 2025, 8:35 鈥� 9:35 AM PT
For more information and to register for this event, please visit .
About the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Launched in 2009, the Ophthalmology Innovation Summit serves to showcase novel therapies in development for unmet needs in ophthalmic disease and vision disorders, bringing together entrepreneurs, ophthalmic start-up companies, clinical thought leaders, industry executives and investment professionals to facilitate an exchange of information and connections to drive innovation in the retina, anterior segment, and optometry.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA鈩� (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA鈩� (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA鈩� (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA鈩� (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA鈩�, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
FAQ
When is Outlook Therapeutics (OTLK) presenting at the OIS Retina Innovation Summit 2025?
Who will be presenting for Outlook Therapeutics (OTLK) at the OIS Retina Summit?
What is Outlook Therapeutics' (OTLK) main focus as a company?
Where is the 8th Annual OIS Retina Innovation Summit being held?
